HRTX · Heron Therapeutics, Inc. · Webcasts, Transcripts & Audio
$0.27
+0.01 (+2.23%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 9, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If the payment of the debt is accelerated, absent any additional funding, cash flows from our operations will be insufficient to repay such debt in full. Therefore, if all outstanding amounts under the Working Capital Facility Agreement are accelerated, management expects there will be substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.”View the 10-Q filed Nov 9, 2026
Market Cap
$50.25M
Shares
190.27M
Volume · Nov 19
3.61M
Avg daily vol (3M)
4.54M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Heron Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Heron Therapeutics, Inc. (HRTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-09
Heron Therapeutics, Inc. (HRTX) Q3 2026 Earnings Call
Revenue
$35.25M
▼ 7.8% YoY Diluted EPS
$-0.03
Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-10
Heron Therapeutics, Inc. (HRTX) Q2 2026 Earnings Call Transcript
Cautious tone
Cinvanti Brand Competition
Acute Care Franchise Growth
Balance Sheet / Hercules Amendment
Revenue
$37.67M
▲ 1.3% YoY Diluted EPS
$-0.03
Gross margin
69.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Positive tone
Crosslink / Ignite Partnership
Oncology / Sinvanti
Acute Care Portfolio Growth
Revenue
$34.71M
▼ 10.8% YoY Diluted EPS
$-0.04
▼ 500% YoY Gross margin
69.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Heron Therapeutics, Inc. (HRTX) Q4 2025 Earnings Call Transcript
Confident tone
Acute care franchise momentum
No Pain Act reimbursement awareness
CrossLink and distribution programs
Revenue
$40.59M*
▼ 0.5% YoY Gross margin
72.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript
Confident tone
Acute care growth (ZYNRELEF and APONVIE)
CINVANTI stability
PONV guidelines inclusion
Revenue
$38.21M
▲ 16.5% YoY Diluted EPS
$-0.10
Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-08
Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript
Confident tone
ZYNRELEF commercial performance
ZYNRELEF reimbursement and access
APONVIE growth
Revenue
$37.20M
▲ 3.3% YoY Diluted EPS
$-0.02
Gross margin
73.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript
Confident tone
APONVIE adoption in hospitals
ZYNRELEF growth and market expansion
CINVANTI / oncology franchise performance
Revenue
$38.90M
▲ 12.2% YoY Diluted EPS
$0.01
Gross margin
78.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript
Confident tone
ZYNRELEF Growth and Inflection
CINVANTI Competition and Pricing Risk
CrossLink Partnership
Revenue
$40.78M*
▲ 19.1% YoY Gross margin
74.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript
Confident tone
ZYNRELEF Growth Drivers (VAN, NOPAIN, CrossLink)
CINVANTI Recovery and 340B Opportunity
APONVIE Commercial Trajectory
Revenue
$32.81M
▲ 4.4% YoY Diluted EPS
$-0.03
Gross margin
71.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Heron Therapeutics, Inc. (HRTX) Q2 2024 Earnings Call Transcript
Confident tone
ZYNRELEF label expansion and catalysts
CrossLink partnership and sales force expansion
Financial turnaround and cost reduction
Revenue
$36.02M
▲ 13.4% YoY Diluted EPS
$-0.06
Gross margin
70.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
Confident tone
CrossLink partnership and sales force expansion
ZYNRELEF label expansion and product performance
Financial performance and path to profitability
Revenue
$34.67M
▲ 17.1% YoY Diluted EPS
$-0.02
Gross margin
75.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript
Confident tone
Vial Access Needle and Prefilled Syringe development
ZYNRELEF growth and label expansion
No Pain Act and reimbursement
Revenue
$34.23M*
▲ 14% YoY Gross margin
71.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Heron Therapeutics, Inc. (HRTX) Q3 2023 Earnings Call Transcript
Revenue
$31.43M
▲ 18.4% YoY Diluted EPS
$-0.17
Gross margin
42.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Heron Therapeutics, Inc. (HRTX) Q2 2023 Earnings Call Transcript
Revenue
$31.76M
▲ 15% YoY Diluted EPS
$-0.35
Gross margin
36.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Heron Therapeutics, Inc. (HRTX) Q1 2023 Earnings Call Transcript
Revenue
$29.61M
▲ 26.3% YoY Diluted EPS
$-0.27
Gross margin
43.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Heron Therapeutics, Inc. (HRTX) Q4 2022 Earnings Call Transcript
Revenue
$30.03M*
▲ 45.4% YoY Gross margin
57.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Heron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Call Transcript
Revenue
$26.56M
▲ 14.3% YoY Diluted EPS
$-0.38
Gross margin
44.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Heron Therapeutics, Inc. (HRTX) Q2 2022 Earnings Call Transcript
Revenue
$27.63M
▲ 23.1% YoY Diluted EPS
$-0.55
Gross margin
41.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Heron Therapeutics, Inc. (HRTX) Q1 2022 Earnings Call Transcript
Revenue
$23.46M
▲ 17.2% YoY Diluted EPS
$-0.63
Gross margin
51.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Heron Therapeutics, Inc. (HRTX) Q4 2021 Earnings Call Transcript
Revenue
$20.66M*
▲ 0.2% YoY Gross margin
47.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Heron Therapeutics, Inc. (HRTX) Q3 2021 Earnings Call Transcript
Revenue
$23.23M
▲ 16.4% YoY Diluted EPS
$-0.51
Gross margin
51.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Heron Therapeutics, Inc. (HRTX) Q4 2020 Earnings Call
Revenue
$20.61M
▼ 41.3% YoY Gross margin
54.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY19 · Q4
2020-01-13
Heron Therapeutics, Inc. (HRTX) Q4 2019 Earnings Call
Revenue
$35.08M
▲ 21.6% YoY Gross margin
54.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–23 of 23 webcasts
Key facts
CIK
818033
CUSIP
427746102
13F (30d)
157 filings
141 filers
Visit website
Investor relations